Marques de Sá Inês, Pereira António Dias, Sharma Prateek, Dinis-Ribeiro Mário
Department of Gastroenterology, Portuguese Oncology Institute of Porto, Porto, Portugal.
Department of Gastroenterology, Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Lisbon, Portugal.
Dis Esophagus. 2020 Nov 30. doi: 10.1093/dote/doaa115.
Multiple guidelines on Barrett's esophagus (BE) have being published in order to standardize and improve clinical practice. However, studies have shown poor adherence to them. Our aim was to synthetize, compare, and assess the quality of recommendations from recently published guidelines, stressing similarities and differences. We conducted a search in Pubmed and Scopus. When different guidelines from the same society were identified, the most recent one was considered. We used the GRADE system to assess the quality of evidence. We included 24 guidelines and position/consensus statements from the European Society of Gastrointestinal Endoscopy, British Society of Gastroenterology, American Society for Gastrointestinal Endoscopy, American Gastroenterological Association, American College of Gastroenterology, Australian guidelines, and Asia-Pacific consensus. All guidelines defend that BE should be diagnosed when there is an extension of columnar epithelium into the distal esophagus. However, there is still some controversy regarding length and histology criteria for BE diagnosis. All guidelines recommend expert pathologist review for dysplasia diagnosis. All guidelines recommend surveillance for non-dysplastic BE, and some recommend surveillance for indefinite dysplasia. While the majority of guidelines recommend ablation therapy for low-grade dysplasia without visible lesion, others recommend ablation therapy or endoscopic surveillance. However, controversy exists regarding surveillance intervals and biopsy protocols. All guidelines recommend endoscopic resection followed by ablation therapy for neoplastic visible lesion. Several guidelines use the GRADE system, but the majority of recommendations are based on low and moderate quality of evidence. Although there is considerable consensus among guidelines, there are some discrepancies resulting from low-quality evidence. The lack of high-quality evidence for the majority of recommendations highlights the importance of continued well-conducted research in this field.
为了规范和改进临床实践,已经发布了多项关于巴雷特食管(BE)的指南。然而,研究表明这些指南的遵循情况不佳。我们的目的是综合、比较和评估近期发布的指南中建议的质量,强调异同之处。我们在PubMed和Scopus上进行了检索。当发现来自同一学会的不同指南时,采用最新的指南。我们使用GRADE系统评估证据质量。我们纳入了来自欧洲胃肠内镜学会、英国胃肠病学会、美国胃肠内镜学会、美国胃肠病学会、美国胃肠病学院、澳大利亚指南以及亚太共识的24项指南和立场/共识声明。所有指南都认为,当柱状上皮延伸至食管远端时应诊断为BE。然而,关于BE诊断的长度和组织学标准仍存在一些争议。所有指南都建议由专家病理学家进行异型增生诊断的审查。所有指南都建议对无异型增生的BE进行监测,一些指南还建议对不确定异型增生进行监测。虽然大多数指南建议对无可见病变的低级别异型增生进行消融治疗,但其他指南则建议进行消融治疗或内镜监测。然而,在监测间隔和活检方案方面存在争议。所有指南都建议对有肿瘤可见病变进行内镜切除,然后进行消融治疗。有几项指南使用GRADE系统,但大多数建议基于低质量和中等质量的证据。尽管指南之间存在相当大的共识,但由于证据质量低,仍存在一些差异。大多数建议缺乏高质量证据凸显了在该领域持续开展高质量研究的重要性。